pSivida’s Medidur maintains primary endpoint results at 12 months

Medidur statistically significantly prevented recurrence of posterior uveitis through 12 months, pSivida announced in a press release.Prevention of recurrence of disease was the primary endpoint in a 6-month phase 3 study, which was met with “high statistical significance” (P < .00000001) and which continued to be met through 12 months of follow-up in the current intent to treat analysis.